ADVERSE REACTIONS
Gastrointestinal: The most common side effects of ethionamide are gastrointestinal disturbances including nausea, vomiting, diarrhea, abdominal pain, excessive salivation, metallic taste, stomatitis, anorexia and weight loss. Adverse gastrointestinal effects appear to be dose related, with approximately 50% of patients unable to tolerate 1 gm as a single dose. Gastrointestinal effects may be minimized by decreasing dosage, by changing the time of drug administration, or by the concurrent administration of an antiemetic agent.
Nervous System: Psychotic disturbances (including mental depression), drowsiness, dizziness, restlessness, headache, and postural hypotension have been reported with ethionamide. Rare reports of peripheral neuritis, optic neuritis, diplopia, blurred vision, and a pellagra-like syndrome also have been reported. Concurrent administration of pyridoxine has been recommended to prevent or relieve neurotoxic effects.
Hepatic: Transient increases in serum bilirubin, SGOT, SGPT; Hepatitis (with or without jaundice).
Other: Hypersensitivity reactions including rash, photosensitivity, thrombocytopenia and purpura have been reported rarely. Hypoglycemia, hypothyroidism, gynecomastia, impotence, and acne also have occurred. The management of patients with diabetes mellitus may become more difficult in those receiving ethionamide.
|
REPORTS OF SUSPECTED TRECATOR SIDE EFFECTS / ADVERSE REACTIONS
Below is a sample of reports where side effects / adverse reactions may be related to Trecator. The information is not vetted and should not be considered as verified clinical evidence.
Possible Trecator side effects / adverse reactions in 31 year old female
Reported by a health professional (non-physician/pharmacist) from France on 2012-01-12
Patient: 31 year old female
Reactions: Delirium
Adverse event resulted in: hospitalization
Suspect drug(s):
Paser
Dosage: 4 g, bid
Administration route: Oral
Indication: Tuberculosis
Start date: 2011-10-10
Cycloserine
Dosage: 250 mg, qd
Administration route: Oral
Indication: Tuberculosis
Start date: 2011-10-10
End date: 2011-11-15
Moxifloxacin HCL
Dosage: 400 mg, qd
Administration route: Oral
Indication: Tuberculosis
Start date: 2011-10-10
Trecator
Dosage: 500 mg, qd
Administration route: Oral
Indication: Tuberculosis
Start date: 2011-10-10
|
